Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 142.38 Million | USD 219.51 Million | 5.56% | 2022 |
The global phocomelia market size was worth around USD 142.38 million in 2022 and is predicted to grow to around USD 219.51 million by 2030 with a compound annual growth rate (CAGR) of roughly 5.56% between 2023 and 2030.
The report delves deeper into several crucial aspects of the global phocomelia market. It includes a detailed discussion of existing growth factors and restraints. Future growth opportunities and challenges that impact the phocomelia industry are comprehensively addressed in the report.
Phocomelia is a type of rare congenital disorder that is mainly characterized by the underdevelopment, absence, or malformation of limbs, particularly legs, and arms. In people living with the disorder, the affected limbs may be either extremely short in which the hands of the feet are directly to the trunk of the body or they may be completely absent. The term ‘phocomelia’ has Greek origins where ‘phoke’ stands for ‘seal’ and ‘melos’ defines ‘limb’. In the human medical context, phocomelia refers to developmental anomalies.
Growing advancements in medical technology to trigger the market growth
The global phocomelia market is projected to grow owing to the increasing advancements in medical technology especially in the fields of prosthetics and orthotics. The former refers to the practice of prosthesis which deals with replacing a missing body part with an artificial impact or device. These objects are intended to allow a patient to live a normal life by restoring the normal functions of the missing and replaced body part. With the advent of technology and growing research & development, there has been a noted growth in the quality of prosthetic devices and postoperative care. Medical professionals now have access to improved materials, designs, and manufacturing processes which has resulted in the development of more comfortable and functional prosthetic limbs which ultimately improved patient’s quality of life.
Availability of limited treatment options for phocomelia to restrict market expansion
The condition, phocomelia, is a complex body anomaly. Although there has been significant growth in medical technology, the development of effective and accessible treatment currently remains a cause of concern in the global healthcare industry. Several countries lack robust medical infrastructure for treating basic medical conditions and in such economies, treatment of advanced conditions such as phocomelia remains significantly unexplored. Additionally, there is a lack of specialized healthcare services, including prosthetics, orthotics, and rehabilitation programs which further adds to the less number of people opting for this treatment.
Research and development for understanding underlying genetic causes of the disease to provide growth opportunities
The phocomelia industry is expected to gain more momentum owing to the increasing research & development (R&D) activities undertaken by several private healthcare companies and government-aided projects to learn more about the underlying genetic causes of phocomelia. This includes investments toward exploring regenerative medicine techniques and investigating potential pharmaceutical interventions. For instance, in December 2022, the National Library of Medicine published a study on understanding the characteristics and prevalence of phocomelia and amelia in Finland.
Lack of accessibility to advanced medical care may pose a challenge to further market expansion
Phocomelia requires specialized treatment and medical care. There is a considerable lack of access to such advanced specialized healthcare services which include pediatric orthopedic surgeons, genetic counselors, and rehabilitation facilities. Moreover, the ongoing war between Russia-Ukraine and several other nations globally has disrupted well-established healthcare systems. In December 2021, Doctors Without Borders (MSF) organizations reported that nearly 300,000 Palestinians in the West Bank of Palestine face severe challenges which barred them from having access to primary health care.
The global phocomelia market is segmented based on causes, symptoms, mutations, treatment, and region,
Based on causes, the global market segments are alcohol or cocaine, maternal intake of thalidomide, blood flow problems, gestational diabetes, and X-ray radiation. The leading cause of phocomelia is the maternal intake of thalidomide which is a teratogen. Multiple research studies have helped the medical community to link several cases of phocomelia to the consumption of thalidomide. Alcohol consumption during pregnancy is linked with a condition known as fetal alcohol syndrome (FAS) which also leads to several developmental abnormalities and phocomelia can occur in some cases of FAS. So far, consumption of cocaine, blood flow problems, gestational diabetes, and X-ray radiation have not been linked to phocomelia but they may have potential adverse effects on fetal development. As per claims by the National Institute of Health (NIH), phocomelia occurs in nearly 0.62 live births per every 100,000 patients.
Based on symptoms, the phocomelia industry is divided into mental deficiencies, shortened or missing limbs, malformation of the uterus, urethra, kidney, or heart, shorter neck length, problems with blood clotting, migraines, and vomiting.
Based on mutations, the global market is divided into spontaneous genetic mutations and inherited mutations. There is evidence to suggest that both spontaneous genetic and inherited mutations can lead to phocomelia. The former mutation occurs during the formation of an individual's reproductive cells or early stages of embryo development. This type is not inherited by parents but arose due to random genetic changes. Inherited mutations are passed from parents to offspring and may either be present in the reproductive cells of one or both parents. A study published on the NIH webpage in November 2015 titled Phocomelia: Case report and differential diagnosis stated that children with both parents acting as carriers had a 25% chance of developing sporadic phocomelia. However, it is crucial to obtain a reliable family history before coming to conclusions.
Based on treatment, the phocomelia industry is divided into therapy, prosthetics, and surgery.
Report Attributes | Report Details |
---|---|
Report Name | Phocomelia Market Research Report |
Market Size in 2022 | USD 142.38 Million |
Market Forecast in 2030 | USD 219.51 Million |
Growth Rate | CAGR of 5.56% |
Number of Pages | 204 |
Key Companies Covered | Teva Pharmaceutical Industries Ltd., Smaart Pharmaceuticals, Tiefenbacher API + Ingredients GmbH & Co. KG, Cambrex Corporation, Hangzhou Jinlan Pharmaceutical Technology Development Co. Ltd., Emcure Pharmaceuticals, Össur, Hanger Clinic, Ottobock, Fillauer LLC, WillowWood, Blatchford Group, Endolite, Freedom Innovations, College Park Industries, and Touch Bionics. |
Segments Covered | By Causes, By Symptoms, By Mutations, By Treatment, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to dominate with the highest growth
The global phocomelia market is projected to witness the highest growth in North America mainly due to the presence of a robust medical infrastructure and the successful conduct of several advanced or complex prosthetic surgeries in the US. The region has registered high medical tourism in the last decade as the United States has one of the best healthcare architecture in the world. A 2011 report on the NIH website showed that Brazil registered a high number of prenatal exposure to thalidomide which is a leading cause of the condition.
Trade relations between the US and Brazil are considered one of the strongest in the world. In 2021, the US medical device export to the US reached USD 947 million as per the International Trade Administration. Although the number of US patients with phocomelia is relatively low, the increasing number of people visiting from across the globe to the US for prosthetic surgeries could trigger higher regional demand.
The global phocomelia market is led by players like:
By Causes
By Symptoms
By Mutations
By Treatment
FrequentlyAsked Questions
Phocomelia is a type of rare congenital disorder that is mainly characterized by the underdevelopment, absence, or malformation of limbs, particularly legs, and arms.
The global phocomelia market is projected to grow owing to the increasing advancements in medical technology especially in the fields of prosthetics and orthotics.
According to study, the global phocomelia market size was worth around USD 142.38 million in 2022 and is predicted to grow to around USD 219.51 million by 2030.
The CAGR value of the phocomelia market is expected to be around 5.56% during 2023-2030.
The global phocomelia market is projected to witness the highest growth in North America mainly due to the presence of a robust medical infrastructure and the successful conduct of several advanced or complex prosthetic surgeries in the US.
The global phocomelia market is led by players like Teva Pharmaceutical Industries Ltd., Smaart Pharmaceuticals, Tiefenbacher API + Ingredients GmbH & Co. KG, Cambrex Corporation, Hangzhou Jinlan Pharmaceutical Technology Development Co., Ltd., and Emcure Pharmaceuticals along with leading prosthetics makers such as Össur, Hanger Clinic, Ottobock, Fillauer LLC, WillowWood, Blatchford Group, Endolite, Freedom Innovations, College Park Industries, and Touch Bionics.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed